Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey Boggis who wrote (363)	4/5/1999 1:07:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 550

To all: Quick respond on 60-Min. Well balanced presentation. Promising and hopefully initial results with SU5416 with caution regards the cure for cancer pts. Very responsive journalism on anti-angiogenesis approach and many should follow this example. Regards the SU5416, I am more than surprised with this good results. I was aware of drug initial response in KS pts and some disease stabilization in lung and colon cancer, but ~27% objective response in cancer end-stage PI phase for cytostatic drug is more than Sugen was hoped for. If there is no problem in combining SU5416 (as well as SU6668 and other anti-angio drugs candidates from SUGN and other bts) with potent cytotoxic drug (drug interaction or some unexpected side effect, which should never be a-priory overlooked), then there is real hope for many cancer pts. Thalidomide and its results is first step in new era of the cancer therapy and I hope that many new anti-angio (like SU5416) drug will follow. Miljenko